MorphoSys AG (NASDAQ:MOR) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 129,400 shares, an increase of 24.8% from the March 31st total of 103,700 shares. Based on an average daily volume of 63,800 shares, the short-interest ratio is currently 2.0 days.
A number of analysts have commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of MorphoSys in a research note on Thursday, April 8th. SVB Leerink reaffirmed a “market perform” rating on shares of MorphoSys in a research note on Monday, March 29th. Zacks Investment Research lowered shares of MorphoSys from a “hold” rating to a “sell” rating in a research note on Wednesday, March 24th. Finally, Morgan Stanley reaffirmed an “equal weight” rating on shares of MorphoSys in a research note on Monday, March 29th. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $38.00.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. lifted its position in shares of MorphoSys by 17.2% in the first quarter. Envestnet Asset Management Inc. now owns 30,533 shares of the company’s stock worth $666,000 after purchasing an additional 4,492 shares in the last quarter. Henry James International Management Inc. increased its holdings in MorphoSys by 62.4% in the first quarter. Henry James International Management Inc. now owns 91,112 shares of the company’s stock worth $1,986,000 after buying an additional 35,000 shares during the last quarter. Capital Asset Advisory Services LLC acquired a new position in MorphoSys in the fourth quarter worth approximately $233,000. JPMorgan Chase & Co. increased its holdings in MorphoSys by 1,179.7% in the fourth quarter. JPMorgan Chase & Co. now owns 3,404 shares of the company’s stock worth $97,000 after buying an additional 3,138 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in MorphoSys in the fourth quarter worth approximately $868,000. 3.06% of the stock is owned by institutional investors and hedge funds.
MorphoSys (NASDAQ:MOR) last posted its quarterly earnings results on Monday, March 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.42. The business had revenue of $42.99 million during the quarter. MorphoSys had a net margin of 8.76% and a return on equity of 4.51%. Research analysts expect that MorphoSys will post 0.38 earnings per share for the current year.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.